Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. No safety signals were identified.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.
• 2 METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo.
• 3 The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: